Business UpdateJul 7, 2026, 08:32 AM
Veru to Present Enobosarm Data at Obesity Summit
AI Summary
Veru Inc. announced it will present at the 2026 4th Annual Obesity & Weight Loss Drug Development Summit, highlighting its enobosarm program for cardiometabolic and inflammatory diseases. The company's CEO and CSO will deliver presentations on July 14-15, 2026, focusing on combining GLP-1s with Selective Androgen Receptor Modulators (SARMs) to prevent muscle loss in sarcopenic obesity and advancing regulatory strategies. The update also detailed the ongoing Phase 2b PLATEAU clinical study and positive results from the completed Phase 2b QUALITY study for enobosarm.
Key Highlights
- Veru Inc. will present at the 2026 4th Annual Obesity & Weight Loss Drug Development Summit on July 14-16, 2026.
- CEO Mitchell Steiner will present on combining GLP-1s with SARMs for sarcopenic obesity in geriatrics on July 15, 2026.
- CSO Gary Barnette will present on advancing regulatory frontiers for weight loss drugs on July 14, 2026.
- The Phase 2b PLATEAU clinical study for enobosarm in combination with semaglutide is ongoing, enrolling approximately 200 older patients.
- Interim analysis for the PLATEAU study is expected in Q1 2027, with final topline data in Q4 2027.
- The completed Phase 2b QUALITY study showed enobosarm preserved lean mass and physical function, and augmented fat loss with semaglutide.
Price Impact
More from VERU